Vitae Pharmaceuticals, Inc. Announces Promising Data for VTP-4, Drug Candidate Advancing Toward Clinical Testing for the Treatment of Atherosclerosis
9/7/2012 10:29:00 AM
More...
|
Vitae Pharmaceuticals, Inc. Secures $15 Million Senior Credit Facility
1/19/2012 7:51:48 AM
More...
|
Vitae Pharmaceuticals, Inc. to Present at the 30th Annual JP Morgan Healthcare Conference
1/5/2012 8:00:25 AM
More...
|
Vitae Pharmaceuticals, Inc. CEO Jeffrey Hatfield Joins the Biotechnology Industry Organization (BIO)'s Board of Directors
10/5/2011 10:06:56 AM
More...
|
Vitae Pharmaceuticals, Inc. Reports Positive Clinical Data in Chronic Kidney Disease Program at the American Diabetes Association's 71st Scientific Sessions
6/27/2011 9:12:56 AM
More...
|
Vitae Pharmaceuticals, Inc. Hires Christine Brennan, Ph.D. as Chief Business Officer
7/14/2010 9:54:44 AM
More...
|
Vitae Pharmaceuticals, Inc. Receives $14 Million Milestone Payment as Boehringer Ingelheim Corporation Advances Lead Compound into Phase I Clinical Trials
6/29/2010 6:34:38 AM
More...
|
Vitae Pharmaceuticals, Inc. to Present at Windhover Information Inc.'s Annual Therapeutic Area Partnerships Conference
11/11/2009 9:14:07 AM
More...
|
Vitae Pharmaceuticals, Inc. Receives $8 Million Payment from Boehringer Ingelheim Corporation (JOBS) for Achievement of 11beta-HSD-1 Program Milestone
9/29/2009 7:28:58 AM
More...
|
Vitae Pharmaceuticals, Inc. Initiates Phase 1 Trial of Novel Renin Inhibitor
9/21/2009 9:01:54 AM
More...
|
|